MDT

96.27

-0.09%↓

A

136.88

-0.74%↓

VEEV

224.08

+0.22%↑

HQY

92.63

-0.52%↓

PHR.US

16.99

+0.47%↑

MDT

96.27

-0.09%↓

A

136.88

-0.74%↓

VEEV

224.08

+0.22%↑

HQY

92.63

-0.52%↓

PHR.US

16.99

+0.47%↑

MDT

96.27

-0.09%↓

A

136.88

-0.74%↓

VEEV

224.08

+0.22%↑

HQY

92.63

-0.52%↓

PHR.US

16.99

+0.47%↑

MDT

96.27

-0.09%↓

A

136.88

-0.74%↓

VEEV

224.08

+0.22%↑

HQY

92.63

-0.52%↓

PHR.US

16.99

+0.47%↑

MDT

96.27

-0.09%↓

A

136.88

-0.74%↓

VEEV

224.08

+0.22%↑

HQY

92.63

-0.52%↓

PHR.US

16.99

+0.47%↑

Search

PerkinElmer Inc

Open

SectorHealthcare

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

-8.6M

47M

Sales

-21M

699M

P/E

Sector Avg

50.397

78.892

EPS

0.4

Dividend yield

0.29

Profit margin

6.675

Employees

11,000

EBITDA

-14M

181M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+14.96% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.29%

2.38%

Next Ex Dividend date

16 sty 2026

Market Stats

By TradingEconomics

Market Cap

71M

11B

Previous open

0

Previous close

0

News Sentiment

By Acuity

16%

84%

13 / 374 Ranking in Healthcare

PerkinElmer Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 gru 2025, 22:03 UTC

Major Market Movers

Mining Stocks Slip Near the End of Stellar Year

29 gru 2025, 15:57 UTC

Major Market Movers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 gru 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Operate From Singapore

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 gru 2025, 23:37 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Integrate Manus Service Into Products

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 gru 2025, 23:35 UTC

Acquisitions, Mergers, Takeovers

Manus to Join Meta Platforms

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Raise Values Kraken at US$8.65 Billion

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin's Kraken Stake to Remain at 22.7%

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin: Additional Interest Offsets Dilution From Raise

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 gru 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 gru 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 gru 2025, 20:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 gru 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Comparison

Price change

PerkinElmer Inc Forecast

Price Target

By TipRanks

14.96% upside

12 Months Forecast

Average 111.22 USD  14.96%

High 123 USD

Low 100 USD

Based on 10 Wall Street analysts offering 12 month price targets forPerkinElmer Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

5

Buy

5

Hold

0

Sell

Sentiment

By Acuity

13 / 374 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat